
What We're Reading: FTC Launches PBM Inquiry; FDA Advisers Recommend Novavax; Drug Prices Soar
The Federal Trade Commission (FTC) launched an inquiry into the practices of pharmacy benefit managers; FDA advisers overwhelmingly support approval of Novavax, a new COVID-19 vaccine; drug prices soar to 20% annual inflation.
FTC Opens Inquiry Into PBMs
The 6 largest pharmacy benefit managers (PBMs) will have to provide information and records on their business practices due to a new Federal Trade Commission (FTC) inquiry.
FDA Advisers Recommend Novavax Vaccine
Novavax’s COVID-19 vaccine received overwhelming approval from the experts who advise the FDA on drug and vaccine approvals, according to
Drug Prices Soar to $180,000 Per Year
The annual inflation rate for new drug prices has soared to 20%, with a median launch price of a new drug in the US increasing from $2115 in 2008 to $180,007 in 2021, according to
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.